Julie K. Quick, MD

Professional Background

Dr. Anjulie (Julie) Quick received a B.S. in Biochemistry from the University of Tulsa, Oklahoma and her M.D. from Creighton University School of Medicine in Omaha, NE. She completed her internal medicine internship and ophthalmology residency at the University of Kansas School of Medicine. She joined KU Eye/Department of Ophthalmology at the University of Kansas in 2017 as a Clinical Instructor and was promoted to Assistant Professor in 2018. She is the Department's Medical Education Coordinator.

• BS, Biochemistry, University of Tulsa, Tulsa, OK
• MD, Ophthalmology, Creighton University School of Medicine, Omaha, NE
• Internship, Internal Medicine, University of Kansas School of Medicine, Kansas City, KS
• Residency, Ophthalmology, University of Kansas, Department of Ophthalmology, Prairie Village, KS

• Board Certification, American Board of Ophthalmology
• Controlled Substance Registration, Drug Enforcement Agency
• MD, Arizona Medical Board
• Medical Doctor, Kansas Board of Healing Arts

• Kansas City Society of Ophthalmology and Otolaryngology, Co-Chair, 2024 - Present
• Kansas City Society of Ophthalmology and Otolaryngology, Ophthalmology Journal Club, Co-Chair, 2024 - Present
• Kansas City Society of Ophthalmology and Otolaryngology, Member, 2018 - Present
• Kansas Society of Eye Physicians and Surgeons, Member, 2018 - Present
• KUMC Resident Council, Resident Council, Member, 2015 - 2017
• KUMC Resident Council, In-Service Committee, Member, 2015 - 2017
• American Academy of Ophthalmology, Fellow, 2014 - Present

---

Research

Overview

Dr. Quick is very active in research projects, both internally and in collaboration with other departments at the University of Kansas. She is the Principal Investigator on two studies and Sub-Investigator on 37 other studies. As a comprehensive ophthalmologist, her goal is to provide thorough eye care to patients of all ages. Dr. Quick works to educate patients while providing the safest, most advanced medical and surgical eye care.

• Intracameral Antibiotics, University of Kansas, Department of Ophthalmology
• Ocugen - Characterization of Corneal Epithelial Changes in Participants Treated with Belantamab Mafodatin, University of Kansas, Department of Ophthalmology
• A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer, University of Kansas Department of Ophthalmology
• A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement (FIGHT-302) , University of Kansas, Department of Ophthalmology
• A Phase 1b Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination with Immune Checkpoint Inhibitor (CPI) Therapy for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer, IRB
• SGN22E – EV-103 – A Phase 1b Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination with Immune Checkpoint Inhibitor (CPI) Therapy for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer, University of Kansas, Department of Ophthalmology
• A Multicenter, Double-Blind, Parallel-Group, Add-on, Superiority Study to Compare the Efficacy and Safety of Multiple Sclerosis who are Treated with Dimethyl fumarate (Tecfidera), IRB
• A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafaneib + Binimetinib + Cetuximb in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer, IRB
• A Phase 1b Dose-Escalation and Dose-Expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination with Immune Checkpoint Inhibitor (CPI) Therapy for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer, IRB
• A Phase 2 Open-Label Trial of Tisotumab Vedotin (HuMax-TF-ADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer, IRB
• A Phase II, Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation, IRB

• Brass, Connor, Quick, Anjulie., K, Singh, Ajay. 2019. Dexamethasone Intravitreal Implant for Uveitic Macular Edema in the Setting of Multiple Sclerosis. American Journal of Ophthalmology Case Reports
• Rohowetz, Landon., J, Quick, Anjulie., K. 2019. A 51-year-old woman with binocular diplopia and unilateral ptosis. Digital Journal of Ophthalmology, 25 (3), 41-44. http://www.djo.harvard.edu/print.php?url=/physicians/gr/3884&print=1